Through the HCS we identified a novel mechanism centered by cyclin dependent kinase inhibitor 3 (CDKN3) that regulates neuroblastoma cell differentiation, and we further investigated the clinical relevance of this regulatory mechanism in neuroblastoma patient prognosis based on published neuroblastoma patient datasets. Here, CDKN3 is linked to neuroblastoma.